129 related articles for article (PubMed ID: 2338419)
1. Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies.
Janmohamed RM; Leyland MJ; Kelly J; Farrell I
J Antimicrob Chemother; 1990 Mar; 25(3):407-12. PubMed ID: 2338419
[TBL] [Abstract][Full Text] [Related]
2. Imipenem-cilastatin monotherapy in severe infections accompanying hematological malignancies.
Urabe A; Takaku F; Mizoguchi H
Jpn J Med; 1991; 30(5):420-3. PubMed ID: 1803041
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis.
Chan CY; Lai KN; Lam AW; Li PK; Chung WW; French GL
J Antimicrob Chemother; 1991 Feb; 27(2):225-32. PubMed ID: 2055813
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.
Tegeder I; Bremer F; Oelkers R; Schobel H; Schüttler J; Brune K; Geisslinger G
Antimicrob Agents Chemother; 1997 Dec; 41(12):2640-5. PubMed ID: 9420033
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients.
Kihara M; Ikeda Y; Shibata K; Masumori S; Ebira H; Shiratori K; Ueda S; Takagi N; Umemura S; Shionoiri H
Clin Nephrol; 1994 Sep; 42(3):193-7. PubMed ID: 7994939
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of imipenem/cilastatin during continuous arteriovenous hemofiltration.
Przechera M; Bengel D; Risler T
Contrib Nephrol; 1991; 93():131-4. PubMed ID: 1802563
[No Abstract] [Full Text] [Related]
8. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
[TBL] [Abstract][Full Text] [Related]
9. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD).
Vos MC; Vincent HH; Yzerman EP
Intensive Care Med; 1992; 18(5):282-5. PubMed ID: 1527259
[TBL] [Abstract][Full Text] [Related]
10. [Clinical pharmacokinetics of an imipenem-cilastatin combination].
Singlas E
Presse Med; 1990 Apr; 19(13):598-605. PubMed ID: 2139939
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration.
Alarabi AA; Cars O; Danielson BG; Salmonson T; Wikström B
J Antimicrob Chemother; 1990 Jul; 26(1):91-8. PubMed ID: 2211452
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function.
Pietroski NA; Graziani AL; Lawson LA; Bland JA; Rogers JD; MacGregor RR
Antimicrob Agents Chemother; 1991 May; 35(5):972-5. PubMed ID: 1854179
[TBL] [Abstract][Full Text] [Related]
13. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
[TBL] [Abstract][Full Text] [Related]
14. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients.
Keller E; Fecht H; Böhler J; Schollmeyer P
Nephrol Dial Transplant; 1989; 4(7):640-5. PubMed ID: 2510062
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101.
Norrby SR; Burman LA; Sassella D; Corigli R; Cassinelli G; Franceschi G; Dornbusch K
J Antimicrob Chemother; 1990 Mar; 25(3):371-83. PubMed ID: 2338416
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL
Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
[TBL] [Abstract][Full Text] [Related]
17. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
Infection; 1996; 24(6):480-4. PubMed ID: 9007599
[TBL] [Abstract][Full Text] [Related]
18. The penetration of imipenem/cilastatin into ascitic fluid in patients with chronic liver disease.
Rolando N; Wade JJ; Philpott-Howard JN; Casewell MW; Williams R
J Antimicrob Chemother; 1994 Jan; 33(1):163-7. PubMed ID: 8157557
[No Abstract] [Full Text] [Related]
19. Imipenem/cilastatin: evolution of the sustained-release intramuscular formulation.
Kahan FM; Rogers JD
Chemotherapy; 1991; 37 Suppl 2():21-5. PubMed ID: 1879183
[TBL] [Abstract][Full Text] [Related]
20. [Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase].
Wang H; Peng Y; Xiao G
Zhonghua Shao Shang Za Zhi; 2000 Dec; 16(6):349-51. PubMed ID: 11876899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
